| Literature DB >> 35815084 |
Ghaneemah Malik Hamadi1, Sally Fadhel Lafta2.
Abstract
Recurrent miscarriage (RM) is defined as the loss of pregnancy three or more consecutive times in the first and second trimester, which in some cases occurs due to immune abnormalities. This study aimed to assess some immunological parameters in women with recurrent miscarriages, including the level of antiphospholipid antibody (APA), anticardiolipin (ACA), antinuclear antibody (ANA), complement C3 and C4, and interleukine-3 (IL-3). We included 100 patients together with 100 healthy women as a control. ELIZA was used to measure some types of autoantibodies. APA and ACA significantly increased (P≤0.05) in patients compared to control. In addition, 29% of the patients were positive for antinuclear antibodies (ANA), while the control subjects had negative results for these autoantibodies. Regarding the complement, the serum levels of C3 and C4 were significantly elevated in the serum level of patients when compared to the control group, but in treated patients (heparin and low-dose aspirin), the levels of the complement (C3 and C4) showed a significant decrease in patients compared to total controls. Cytokine level (IL-3) significantly decreased in untreated patients 302.78 pg/ml compared to treated patients (741.57 pg/ml). Antiphospholipid antibodies are more prevalent among women with recurrent miscarriages and are also believed to be the result of abnormal autoimmune activation.Entities:
Keywords: antiphospholipid; autoantibodies; cytokines; recurrent miscarriage
Mesh:
Substances:
Year: 2022 PMID: 35815084 PMCID: PMC9262261 DOI: 10.25122/jml-2021-0388
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
Antiphospholipid antibody (APA) level in serum of patients and controls.
| APA(IU/ml) | Mean±SE | P-value | |
|---|---|---|---|
| Patients | Controls | ||
|
| 1.12±11.13 | 1.49±0.12 | <0.05 |
|
| 1.22±21.14 | 1.89±0.13 | |
Anticardiolipin antibody (ACA) level in the serum of patients and controls.
| APA(IU/ml) | Mean±SE | P-value | |
|---|---|---|---|
| Patients | Controls | ||
|
| 2.15±9.22 | 1.51±0.26 | <0.05 |
|
| 1.82±20.31 | 1.41±0.12 | |
Antinuclear antibody (ANA) level in the serum of patients and controls.
| Groups | Patients | Controls | ||
|---|---|---|---|---|
| No | % | No. | % | |
|
| 27 | 27.0 | 0 | 0.00 |
|
| 73 | 73.0 | 100 | 100 |
|
| 100 | 100 | ||
Concentration Complements C3 and C4 in serum of patients and controls.
| Groups | Patients with treatments | Patients without treatments | Controls |
|---|---|---|---|
|
| 6.21±89.57 | 10.24±111.19 | 2.68±96.17 |
|
| 1.22±11.89 | 2.52±34.41 | 0.73±29.38 |
Concentration of IL-3 in patients and controls.
| Groups | Patients with treatments | Patients without treatments | Controls |
|---|---|---|---|
|
| 48.05±741.57 | 27.18±302.78 | 59.36±624.12 |